Home » Newsletters » BioWorld Science

BioWorld Science

April 21, 2021

View Archived Issues

Sinocelltech starts phase II/III development of SCTA-01 in COVID-19

First patient infused in phase I study of CD19 RPM CAR-T cell therapy

Krystal Biotech provides development updates for KB-407 and KB-408

Revolution Medicines targets SOS-1 with new compound RMC-0331 for RAS-driven cancers

Baricitinib improves hair regrowth in patients with alopecia areata in second BRAVE-AA trial

FDA places clinical hold on proposed phase II study of KVD-824

Positive interim data presented from phase I portion of the AUGMENT-101 study of SNDX-5613

FDA allows Vincerx Pharma to conduct phase Ib study of VIP-152 in CLL and Richter syndrome

Phase II study application for FB-704A in severe asthma receives approval in Taiwan

ECM2 mutation as a biomarker of response to ICIs in patients with melanoma

Discovery and preclinical characterization of novel KRAS G12C inhibitor, LY-3537982

SEP-363856 is associated with robust improvement in negative symptoms of schizophrenia

Sumitomo Dainippon Pharma patents new compounds for cancer

Fujifilm divulges FGFR inhibitors

New GTPase KRAS mutant inhibitors presented by BeiGene

Pivotal study evaluates ION-373 for Alexander disease

Medshine Discovery patent describes LSD1 inhibitors

King's College London presents adeno-associated viral vectors

Novel STING agonists for antitumor immunotherapy

New molecular imaging and therapy trials open at Hoag

FDA clears IND for phase I trial of Transcenta's bifunctional PD-L1/TGF-beta antibody TST-005

AZD-8853, a new anti-GDF15 antibody for cancer immunotherapy

Initiation of NOBLE Registry for Telix's TLX599-CDx SPECT in prostate cancer

CL-2020 studied for ARDS related to COVID-19 in Japan

Trevena's TRV-027 to be studied in REMAP-CAP study for COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...